Biotechnology company Quotient (stock code: QTNT) recently disclosed that, in addition to the previously announced transaction terms, the company is also eligible to receive milestone payments based on development progress, regulatory approvals, and commercialization performance.

If all phased targets are achieved, the potential total value of this cooperation agreement could reach up to $2.2 billion. The milestone reward mechanism will be triggered in stages, with specific amounts linked to progress in product development, regulatory approval timelines, and market sales performance. This move further highlights the partners' recognition of the commercial potential of the Quotient technology platform, and also provides diversified support for the company's future cash flow.